about
Using O*NET to estimate the association between work exposures and chronic diseasesA novel method for estimating the effects of job conditions on asthma and chronic lung diseaseChronic disease risks from exposure to long-hour work schedules over a 32-Year periodAssociation Between Patient Characteristics and Treatment Procedure Among Patients With Uterine Leiomyomas.Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial FibrillationIschemic Stroke or Systemic Embolism After Transseptal Ablation of Arrhythmias in Patients With Cardiac Implantable Electronic DevicesIncidence and Early Outcomes of Heart Failure in Commercially Insured and Medicare Advantage Patients, 2006 to 2014Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment.Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes.Pacemaker implantation after catheter ablation for atrial fibrillation.Does time pressure create barriers for people to receive preventive health services?Association of worksite wellness center attendance with weight loss and health care cost savings: Mayo Clinic's experience.Medical therapies for heavy menstrual bleeding in women with uterine fibroids: a retrospective analysis of a large commercially insured population in the USA.Dabigatran Versus Warfarin in Relation to Renal Function in Patients With Atrial FibrillationDirect Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial FibrillationTrends and predictors of repeat catheter ablation for atrial fibrillationComparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart diseaseStroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial FibrillationDirect Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other Than Significant Mitral Stenosis and Mechanical Valves: A Meta-AnalysisFinding Order in Chaos: Can Instrumental Variables Help Us Understand Observed Treatment Effects?Clinical trial design data for electrocardiogram artificial intelligence-guided screening for low ejection fraction (EAGLE)Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary FibrosisNOAC dosing and monitoring: really as simple as it seems?
P50
Q23909768-C6AF4681-70BB-4F2D-9CCC-8496F33F2591Q23909771-44D8BE00-EA63-4ABE-8B90-AC40336C7466Q27908558-7B4F4CE2-0EF1-423B-B3A2-01F451B6CDDBQ36399864-1E570AE6-4B75-40A1-9155-09F118D66F5FQ36714127-C79D8ECA-71E0-4AA3-BAB9-ECE4B331C7FCQ36831825-86E2F376-11DF-4CA0-96C6-810FECDE6C1BQ36913526-4A7D1837-E9FE-4B79-98F6-89F8509B2FDFQ37076243-9D0CD5AB-FC99-40A4-B170-18D3D6B547E1Q37607052-5410BE2D-A1A7-42D1-8094-0E9B582EDE09Q37737142-B17A66F2-6DCE-43A9-AE62-5B7B29FA4EE7Q38627421-C2B78187-9E15-4FE1-986F-ABAB538396B6Q41216603-96A70985-DB41-4617-9C69-475F90097982Q41289055-CF9FA142-B090-44EA-A6CC-25FA3A68750EQ47158102-416E97C6-7FA7-4322-B9A4-2B0B6D4BC045Q57907740-2DC6CD7B-659D-45F4-BB3F-D906CCF12C80Q57907741-2A9BF420-DF89-445D-8E02-F0C527EE3317Q86965068-DEE4FB30-2CBB-4EDB-AC65-2D9F1ECF463EQ87329889-53B98BE4-6712-4DE9-8686-3DBF232BD6D0Q87742827-413A17A3-CAA8-4306-AA8D-A147EE2EF9B5Q89266325-7DEC530C-ABF2-4700-8DD0-3CCC7887BFBEQ91870515-92B0AF5F-292F-42A1-850E-409BCFAC3C98Q92191683-93A4A7BD-C076-4554-82D3-C61AC82DBB75Q92439543-F343D1C9-834B-44A8-B9FE-E2150C3CE766Q92479639-BC575561-B87A-4A61-B9CE-0C58DD58B2CE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Xiaoxi Yao
@ast
Xiaoxi Yao
@en
Xiaoxi Yao
@es
Xiaoxi Yao
@nl
type
label
Xiaoxi Yao
@ast
Xiaoxi Yao
@en
Xiaoxi Yao
@es
Xiaoxi Yao
@nl
prefLabel
Xiaoxi Yao
@ast
Xiaoxi Yao
@en
Xiaoxi Yao
@es
Xiaoxi Yao
@nl
P108
P106
P1153
56555633200
P31
P496
0000-0001-9906-7106